EVALUATION OF THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN FOR TREATING HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE UNITED STATES

被引：0
|
作者：
Nechi, R. [1 ]
Rane, A. [2 ]
Karaye, R. [3 ]
Ndikumukiza, C. [2 ]
Alsahali, S. [4 ]
Jatau, A. [5 ]
Zoni, C. R. [6 ]
Alanazi, A. [7 ]
Karaye, I [8 ]
Yunusa, I [9 ]
机构：
[1] Penn State Univ, Hershey, PA USA
[2] MCPHS Univ, Boston, MA USA
[3] Aminu Kano Teaching Hosp, Kano, Nigeria
[4] Qassim Univ, Unaizah Coll Pharm, Dept Pharm Practice, Qasim, Saudi Arabia
[5] Univ Tasmania, Hobart, Tas, Australia
[6] Unconn Hlth, Framingham, CT USA
[7] Massachusetts Coll Pharm & Hlth Sci MCPHS, Dept Pharmaceut Econ & Policy, Sch Pharm, Boston, MA USA
[8] Hofstra Univ, Dept Populat Hlth, Hempstead, NY USA
[9] Univ South Carolina, Columbia, SC USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE342
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS
    Kvamme, I
    de Graaf, G.
    Nekerman, S.
    Gijsbers, S.
    Wester, V
    Hoogendoorn, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
  • [22] Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial
    Lin, Lu
    Xiu, Qiu-ping
    Liu, Fei
    Zhang, Hou-jing
    Chen, Yi-feng
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2023,
  • [23] Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States
    Zueger, Patrick M.
    Kumar, Varun M.
    Harrington, Rachel L.
    Rigoni, Gianna C.
    Atwood, Alicia
    DiDomenico, Robert J.
    Touchette, Daniel R.
    [J]. PHARMACOTHERAPY, 2018, 38 (05): : 520 - 530
  • [24] Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
    Kolovos, Spyros
    Bellanca, Leana
    Groyer, Harinala
    Rosano, Giuseppe
    Gaultney, Jennifer
    Linden, Stephan
    [J]. JOURNAL OF CARDIOVASCULAR MEDICINE, 2023, 24 (10) : 758 - 764
  • [25] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Ghader Mohammadnezhad
    Behniya Azadmehr
    Mehdi Mirheidari
    Nazila Yousefi
    [J]. Cost Effectiveness and Resource Allocation, 20
  • [26] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Mohammadnezhad, Ghader
    Azadmehr, Behniya
    Mirheidari, Mehdi
    Yousefi, Nazila
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
  • [27] Cost-effectiveness of add-on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
    Abushanab, Dina
    Chbib, Salma
    Kaddoura, Rasha
    Al Hail, Moza
    Rouf, Palli Valappila Abdul
    El Kassem, Wessam
    Shah, Jassim
    Nair, Ramesh Kumar Ravindran
    Al-Badriyeh, Daoud
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 404 - 417
  • [28] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    [J]. ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [29] COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS
    Cavusoglu, Y.
    Demir, O.
    Dinc, M.
    Ozsoy, A.
    Erdogan, A.
    Ozer, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S66 - S66
  • [30] Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
    Lin, Xiaohui
    Lin, Minhua
    Liu, Maobai
    Huang, Weiying
    Nie, Xuekun
    Chen, Zichun
    Zheng, Bin
    [J]. JOURNAL OF THORACIC DISEASE, 2022, 14 (05) : 1588 - 1597
12345